L'histoire naturelle au XVIe siècle : regards, lectures et discours sur la nature à travers l'exemple de La nature et diversité des poissons de Pierre Belon (1555)

Plan du travail Nous traiterons de cet aspect historique et contextuel dans la première partie. Les trois premiers chapitres décrivent les fondements antiques et médiévaux de la philosophie naturelle seiziémiste et évoquent l'influence du De animalibus d'Albert le Grand sur les médecins naturalistes. Nous en arriverons alors aux liens qui unissent ces derniers (chapitre IV) et aux conditions matérielles et intellectuelles qui entourent et parfois entravent la parution des ouvrages (chapitre V). Nous nous pencherons ensuite sur l'identité des lecteurs susceptibles d'être intéressés par les traités d'histoire naturelle. Ces lecteurs ont des attentes qui méritent aussi un examen quant à leur origine, car elles conditionnent pour une part variable, mais importante, le contenu des oeuvres (chapitre VI). Confrontés à des critiques, à des obstacles institutionnels parfois séculaires, les médecins naturalistes se défendent pour une part en reprenant les arguments de leurs prédécesseurs médiévaux. Mais nous les verrons mettre en place de nouvelles stratégies, en relation étroite avec le renouveau bien connu de la dialectique et de la rhétorique, qui trouve ses racines en Italie du nord à la fin du XVe siècle. Ce point sera développé dans la seconde partie, qui servira de transition essentielle dans notre exposé. C'est là que nous découvrirons que la rhétorique ne s'impose pas uniquement comme un rituel renouvelé de la dispute médiévale : elle n'entre pas seulement en jeu lorsqu'il s'agit de défendre ses intérêts contre des rivaux ou des adversaires académiques (chapitre VII). Les médecins naturalistes mettent au contraire au point des instruments au service d'un processus heuristique qui s'inspire des nouveaux canons de la rhétorique, dont Rudolph Agricola est un des théoriciens principaux (chapitre VIII). Ces observations nous amèneront à repréciser ce qu'il faut entendre par philosophie naturelle au XVIe siècle, notamment au travers de l'autorité de personnages comme Théodore Gaza (chapitre IX) et à définir les fondements généraux de l'histoire naturelle seiziémiste, en adoptant des points de vue divers : examen des tables des matières d'ouvrages, des réflexions des médecins naturalistes, avec à leur tête Conrad Gesner, ou encore étude de la pénétration de l'histoire naturelle dans quelques récits des voyageurs aux Amériques (chapitre X et XI). Arrivé à ce point de l'exposé, le lecteur aura constaté que la solidité de l'histoire naturelle seiziémiste tient à une stratégie discursive soigneusement élaborée. Le développement détaillé et l'application de ce nouveau processus, qui s'ancre au plus profond du discours descriptif de la nature, seront décrits dans la troisième partie. Nous commencerons par y rappeler quels sont les instruments antiques de la description des particulares, l'accident et la différence, que les médecins naturalistes adaptent à leurs exigences heuristiques (chapitre XII). Nous verrons le rôle de "nota", outil discursif méconnu, qui désigne les éléments décisifs ou arguments par lesquels les médecins naturalistes identifient les espèces décrites par les anciens en les confrontant aux espèces réelles (chapitre XIII). Une fois présenté l'instrument descriptif, se pose la question de son utilisation par les médecins naturalistes et de son évaluation par rapport au fonctionnement de la taxonomie moderne (chapitre XIV). La différence entre les deux regards sur la nature apparaîtra comme fondamentale : les médecins naturalistes assignent à leurs investigations des limites, inhérentes à l'origine sacrée de leur quête, qui relève de la philosophie, elle-même subordonnée à la théologie. Cela se percevra par exemple dans la description des animaux du Nouveau Monde. Les conséquences de cette constatation sont considérables : elles remettent en cause le statut du "savant" du XVIe siècle, qui ne saurait être assimilé à l'observateur extérieur tel que l'érige la science des Lumières. Belon et ses collègues se disent plutôt des "contemplateurs" et des interprètes, ce qui les rapprochent de la figure du poète, avec qui ils entretiennent des rapports ambivalents. C'est la relation même du médecin naturaliste au langage de la nature qui s'en trouve affectée : le savant n'a pas la maîtrise du discours, dans la mesure où les signes qu'il interprète et, dans une certaine mesure, ordonne, du latin : les noms d'espèces, entre autres dans les titres de notices descriptives, pour mieux cerner la relation entre la langue antique et la vernaculaire, ainsi que la notion de langue originelle chez les médecins naturalistes (chapitre XVIII). Les points communs qui émergeront de cette confrontation feront disparaître le clivage anachronique entre langue latine et langue vernaculaire, de même que l'hypothèse de l'insuffisance lexicale de la seconde, dont les médecins naturalistes auraient en vain voulu faire l'instrument de la science moderne (chapitre XIX). Le chapitre XX aura pour but d'établir le lien et l'adéquation entre les caractéristiques du discours descriptif ainsi mises en évidence et les fondements véritables de l'histoire naturelle seiziémiste.

Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?

The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X-Pro/Ala dipeptides from the N-terminus of peptides. DPP IV is responsible of the degradation of the incretin peptide hormones regulating blood glucose levels. Several families of DPP IV inhibitors have been synthesized and evaluated. Their positive effects on the degradation of the incretins and the control of blood glucose levels have been demonstrated in biological models and in clinical trials. Presently, several DPP IV inhibitors, the "gliptins", are approved for type 2 diabetes or are under clinical evaluation. However, the gliptins may also be of therapeutic interest for other diseases beyond the inhibition of incretin degradation. In this Perspective, the biological functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabetes and further therapeutic interest.

Indice d'aptitude général pour le WISC-IV: Normes francophones

La quatrième version de l'échelle d'intelligence de Wechsler pour enfants (WISC-IV) permet le calcul du QI Total et de quatre indices factoriels : compréhension verbale, raisonnement perceptif, vitesse de traitement et mémoire de travail. En 1998, Prifitera et al, ont préconisé le calcul de l'indice d'aptitude général (IAG) comme alternative au quotient intellectuel total (QIT), et cela à partir des scores de compréhension verbale et de raisonnement perceptif. La première étude présentée dans cet article a pour objectif d'établir les normes francophones pour le score IAG du WISC-IV, en utilisant une procédure d'approximation statistique. La deuxième étude vise à examiner la validité de ces normes, en les confrontant à des données recueillies sur un échantillon de 60 enfants. La corrélation entre QIT et IAG est de 0,91 et la différence relative moyenne de 0,18 point. Ces normes permettent d'utiliser le score IAG comme alternative au QIT dans certaines situations diagnostiques.

Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach.

PURPOSE: To optimize conditions for photodynamic detection (PDD) and photodynamic therapy (PDT) of bladder carcinoma, urothelial accumulation of protoporphyrin IX (PpIX) and conditions leading to cell photodestruction were studied. MATERIALS AND METHODS: Porcine and human bladder mucosae were superfused with derivatives of 5-aminolevulinic acid (ALA). PpIX accumulation and distribution across the mucosa was studied by microspectrofluorometry. Cell viability and structural integrity were assessed by using vital dyes and microscopy. RESULTS: ALA esters, especially hexyl-ALA, accelerated and regularized urothelial PpIX accumulation and allowed for necrosis upon illumination. CONCLUSIONS: hexyl-ALA used at micromolar concentrations is the most efficient PpIX precursor for PDD and PDT.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on time to complete cytogenetic (CCR) and major molecular remission (MMR) and progression-free (PFS) and overall survival (OS) was analyzed using data from 1151 Philadelphia chromosome-positive (Ph(+)) CML patients randomized to the German CML Study IV. At diagnosis, 1003 of 1151 patients (87%) had standard t(9;22)(q34;q11) only, 69 patients (6.0%) had variant t(v;22), and 79 (6.9%) additional cytogenetic aberrations (ACAs). Of these, 38 patients (3.3%) lacked the Y chromosome (-Y) and 41 patients (3.6%) had ACAs except -Y; 16 of these (1.4%) were major route (second Philadelphia [Ph] chromosome, trisomy 8, isochromosome 17q, or trisomy 19) and 25 minor route (all other) ACAs. After a median observation time of 5.3 years for patients with t(9;22), t(v;22), -Y, minor- and major-route ACAs, the 5-year PFS was 90%, 81%, 88%, 96%, and 50%, and the 5-year OS was 92%, 87%, 91%, 96%, and 53%, respectively. In patients with major-route ACAs, the times to CCR and MMR were longer and PFS and OS were shorter (P < .001) than in patients with standard t(9;22). We conclude that major-route ACAs at diagnosis are associated with a negative impact on survival and signify progression to the accelerated phase and blast crisis.

Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV

Introduction: Acquired genetic instability in chronic myeloid leukemia (CML) as a consequence of the translocation t(9;22)(q34;q11) and the resulting BCR-ABL fusion causes the continuous acquisition of additional chromosomal aberrations and mutations and thereby progression to accelerated phase (AP) and blast crisis (BC). At least 10% of patients in chronic phase (CP) CML show additional alterations at diagnosis. This proportion rises during the course of the disease up to 80% in BC. Acquisition of chromosomal changes during treatment is considered as a poor prognostic indicator, whereas the impact of chromosomal aberrations at diagnosis depends on their type. Patients with major route additional chromosomal alterations (major ACA: +8, i(17)(q10), +19, +der(22)t(9;22)(q34;q11) have a worse outcome whereas patients with minor route ACA show no difference in overall survival (OS) and progression-free survival (PFS) compared to patients with the standard translocation, a variant translocation or the loss of the Y chromosome (Fabarius et al., Blood 2011). However, the impact of balanced vs. unbalanced (gains or losses of chromosomes or chromosomal material) karyotypes at diagnosis on prognosis of CML is not clear yet. Patients and methods: Clinical and cytogenetic data of 1346 evaluable out of 1544 patients with Philadelphia and BCR-ABL positive CP CML randomized until December 2011 to the German CML-Study IV, a randomized 5-arm trial to optimize imatinib therapy by combination, or dose escalation and stem cell transplantation were investigated. There were 540 females (40%) and 806 males (60%). Median age was 53 years (range, 16-88). The impact of additional cytogenetic aberrations in combination with an unbalanced or balanced karyotype at diagnosis on time to complete cytogenetic and major molecular remission (CCR, MMR), PFS and OS was investigated. Results: At diagnosis 1174/1346 patients (87%) had the standard t(9;22)(q34;q11) only and 75 patients (6%) had a variant t(v;22). In 64 of 75 patients with t(v;22), only one further chromosome was involved in the translocation; In 8 patients two, in 2 patients three, and in one patient four further chromosomes were involved. Ninety seven patients (7%) had additional cytogenetic aberrations. Of these, 44 patients (3%) lacked the Y chromosome (-Y) and 53 patients (4%) had major or minor ACA. Thirty six of the 53 patients (2.7%) had an unbalanced karyotype (including all patients with major route ACA and patients with other unbalanced alterations like -X, del(1)(q21), del(5)(q11q14), +10, t(15;17)(p10;p10), -21), and 17 (1.3%) a balanced karyotype with reciprocal translocations [e.g. t(1;21); t(2;16); t(3;12); t(4;6); t(5;8); t(15;20)]. After a median observation time of 5.6 years for patients with t(9;22), t(v;22), -Y, balanced and unbalanced karyotype with ACA median times to CCR were 1.05, 1.05, 1.03, 2.58 and 1.51 years, to MMR 1.31, 1.51, 1.65, 2.97 and 2.07 years. Time to CCR and MMR was longer in patients with balanced karyotypes (data statistically not significant). 5-year PFS was 89%, 78%, 87%, 94% and 69% and 5-year OS 91%, 87%, 89%, 100% and 73%, respectively. In CML patients with unbalanced karyotype PFS (p<0.001) and OS (p<0.001) were shorter than in patients with standard translocation (or balanced karyotype; p<0.04 and p<0.07, respectively). Conclusion: We conclude that the prognostic impact of additional cytogenetic alterations at diagnosis of CML is heterogeneous and consideration of their types may be important. Not only patients with major route ACA at diagnosis of CML but also patients with unbalanced karyotypes identify a group of patients with shorter PFS and OS as compared to all other patients. Therefore, different therapeutic options such as intensive therapy with the most potent tyrosine kinase inhibitors or stem cell transplantation are required.

Small bowel bacterial overgrowth is found in 71% of IBS patients and associated symptoms respond well to Rifaximin in a phase IV trial

Background a nd A ims: The prevalence of small intestinal bowel bacterial o vergrowth (SIBO) i n patients w ith irritable bowel syndrome (IBS) ranges from 43% to 78% as determined by t he lactulose hydrogen breath (LHBT) t est. Although rifaximine, a non-absorbable antibiotic, h as b een able to decrease I BS s ymptoms i n placebo-controlled r andomized trials, these results were not repeated in phase IV studies. We aimed to assess the prevalence of SIBO in an IBS cohort and to evaluate the response to rifaximin. Methods: I BS p atients f ulfilled Rome III criteria, had an absence of alarm symptoms, n ormal f ecal c alproectin, and normal e ndoscopic workup. They underwent lactulose hydrogen breath t esting (LHBT) for SIBO diagnosis. P atients with SIBO were t reated w ith rifaximine tablets f or 14 d ays. Symptoms were a ssessed by q uestionnaires before rifaximin treatment and at week 6. Results: Hundred-fifty IBS patients were enrolled (76% female, mean age 44 ± 16 years), of whom 106 (71%) were diagnosed with SIBO and consequently treated with rifaximine. Rifaximine treatment s ignificantly reduced the following symptoms as assessed by t he s ymptom q uestionnaire: bloating (5.5 ± 2.6 before vs. 3 .6 ± 2.7 after treatment, p <0.001), flatulence (5 ± 2.7 vs. 4 ± 2.7, p = 0.015), diarrhea (2.9 ± 2.4 vs. 2 ± 2.4, p = 0.005), abdominal pain (4.8 ± 2.7 vs. 3.3 ± 2.5, p <0.001) and resulted in improved overall well-being (3.9 ± 2.4 vs. 2.7 ± 2.3, p <0.001). The LHBT was repeated 2-4 weeks after rifaximine treatment in 6 5/93 (70%) patients. Eradication of SIBO was documented in 85% of all patients (55/65). Conclusions: The results o f our phase IV trial i ndicate that a high proportion of IBS p atients t ested positive f or SIBO. I BS symptoms w ere significantly diminished following a 2-week treatment with rifaximine.

Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils.

PURPOSE: To analyze outcomes after right portal vein embolization extended to segment IV (right PVE + IV) before extended right hepatectomy, including liver hypertrophy, resection rates, and complications after embolization and resection, and to assess differences in outcomes with two different particulate embolic agents. MATERIALS AND METHODS: Between 1998 and 2004, transhepatic ipsilateral right PVE + IV with particles and coils was performed in 44 patients with malignant hepatobiliary disease, including metastases (n = 24), biliary cancer (n = 14), and hepatocellular carcinoma (n = 6). Right PVE + IV was considered if the future liver remnant (FLR; segments II/III with or without I) was less than 25% of the total estimated liver volume (TELV). Tris-acryl microspheres (100-700 microm; n = 21) or polyvinyl alcohol (PVA) particles (355-1,000 microm; n = 23) were administered in a stepwise fashion. Smaller particles were used to occlude distal branches, followed by larger particles to occlude proximal branches until near-complete stasis. Coils were then placed in secondary portal branches. Computed tomographic volumetry was performed before and 3-4 weeks after right PVE + IV to assess FLR hypertrophy. Liver volumes and postembolization and postoperative outcomes were measured. RESULTS: After right PVE + IV with PVA particles, FLR volume increased 45.5% +/- 40.9% and FLR/TELV ratio increased 6.9% +/- 5.6%. After right PVE + IV with tris-acryl microspheres, FLR volume increased 69.0% +/- 30.7% and FLR/TELV ratio increased 9.7% +/- 3.3%. Differences in FLR volume (P = .0011), FLR/TELV ratio (P = .027), and resection rates (P = .02) were statistically significant. Seventy-one percent of patients underwent extended right hepatectomy (86% after receiving tris-acryl microspheres, 57% after receiving PVA). Thirteen patients (29%) did not undergo resection (extrahepatic spread [n = 9], inadequate hypertrophy [n = 3], other reasons [n = 1]). No patient developed postembolization syndrome or progressive liver insufficiency after embolization or resection. One death after resection occurred as a result of sepsis and hemorrhage. Median hospital stays were 1 day after right PVE + IV and 7 days after resection. CONCLUSION: Transhepatic ipsilateral right PVE + IV with use of particles and coils is a safe, effective method for inducing contralateral hypertrophy before extended right hepatectomy. Embolization with small spherical particles provides improved hypertrophy and resection rates compared with larger, nonspherical particles.

Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.

The choice of design between individual randomisation, cluster or pseudo-cluster randomisation is often made difficult. Clear methodological guidelines have been given for trials in general practice, but not for vaccine trials. This article proposes a decisional flow-chart to choose the most adapted design for evaluating the effectiveness of a vaccine in large-scale studies. Six criteria have been identified: importance of herd immunity or herd protection, ability to delimit epidemiological units, homogeneity of transmission probability across sub-populations, population's acceptability of randomisation, availability of logistical resources, and estimated sample size. This easy to use decisional method could help sponsors, trial steering committees and ethical committees adopt the most suitable design.